Business in the Burbs

FDA needs more time to review pain medication

January

Progenics Pharmaceuticals Inc., an Eastview-based biotechnology research company, and Wyeth said this morning the U.S. Food and Drug Administration needs an extra three months to review their application to market a drug to treat constipation caused by certain pain medications.

The government agency now needs until April 30 to review the application for subcutaneous methylnaltrexone, the companies said in a joint release.

The companies are developing the drug for terminally patients with conditions such as cancer or AIDS and who have taken opiods to relieve pain.

This entry was posted on Thursday, January 10th, 2008 at 12:57 pm by Allan Drury. You can follow any responses to this entry through the RSS 2.0 feed.
Category: Corporate doings

Print | Email

It is a condition of your use of the comment features associated with the blogs that you do not: Use the site to post or transmit any unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane or indecent information of any kind, including without limitation any transmissions constituting or encouraging conduct that would constitute a criminal offense, give rise to civil liability or otherwise violate any local, state, national or international law. You alone are responsible for the material you post or send. Refer to the Terms of Service.